Cancer - AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
What is the goal of this study?
The goal of this study is to answer the following question: What is the two-year treatment-free remission rate of children and young adults with chronic myeloid leukemia - chronic phase (CML-CP) after taking tyrosine kinase inhibitors (TKI) for at least three years?
Researchers also hope to estimate the remission rate after one year in patients who have to restart TKI therapy.
Who can join the study?
This study may be a good for for children and young adults who:
- Were diagnosed with chronic myeloid leukemia - chronic phase (CML-CP) at less than 18 years of age and are currently less than 25 years of age
- Have received any TKI therapy for a minimum of three consecutive years at time of enrollment and are willing to discontinue TKI therapy
You can read more about the eligibility criteria for this study on clinicaltrials.gov.
Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.
What will happen if my child takes part in this study?
Participants in this study will:
- Stop taking TKI medication
- Be monitored for disease by having blood drawn every four weeks for the first year, every six weeks for the second year, then every 12 weeks for the third year
- Complete questionnaires and have neurocognitive testing if eligibility criteria is met
If a participant relapses, they must restart a TKI therapy, preferably the same one used previously.
Who can I contact for more information?
Please email the research coordinator or call the study team at (206) 987-2106 for more information about this study.